Giulio Viceconte

7PUBLICATIONS
3CO-AUTHORS
Gene and molecular therapyImmunology not elsewhere classifiedEpidemiological methodsNanomedicineMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 05, 2025
Activity of sotrovimab in early clearance of SARS CoV-2 infection in severe immunocompromised patients: results of a prospective, monocentric study.

Giulio Viceconte, Antonio Riccardo Buonomo, Emilia Trucillo

|Jul 11, 2025
Outbreak of Human Neuroinvasive West Nile Virus Infection in Campania, Italy, August-September 2024.

Nunzia Esposito, Giulio Viceconte, Lidia Festa

|Mar 20, 2025
Long-term Safety and Effectiveness of Rezafungin Treatment in Candidemia and Invasive Candidiasis: Results From an Early Access Program in Italy and Germany.

Filippo Trapani, Giulio Viceconte, Valentina Morena

|Dec 11, 2024
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single-centre study.

I Gentile, G Viceconte, F Cuccurullo

|Apr 04, 2022
Correction to: Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.

Antonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese

|Feb 15, 2022
Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study.

Antonio Riccardo Buonomo, Giulio Viceconte, Massimiliano Calabrese

Pageof 2

Frequent Collaborators

1 joint publications

Filippo Trapani

1 joint publications

Giusy Tiseo

1 joint publications

Giovanni Mori